Morgan Stanley, CLSA cut Cipla ratings on earnings
MUMBAI (Reuters) - Morgan Stanley and CLSA downgraded their ratings on Cipla Ltd (CIPL.NS) a day after the Indian drugmaker reported a slower-than-expected rise in its October-December net profit.
Morgan Stanley cut its ratings to "equal-weight" from "overweight", citing slower growth prospects on the back of limited niche drug launches, lower margins and a higher tax rate. The bank also cut its price target to 414 rupees from 437 rupees.
CLSA cut its ratings on Cipla to "underperform" from "outperform", citing disappointing margins in the October-December quarter and expectations near-term earnings growth will be slower due a higher base. The bank cut its price target to 415 rupees from 475 rupees.
(Reporting by Abhishek Vishnoi and Rafael Nam; Editing by Subhranshu Sahu)
- Tweet this
- Share this
- Digg this
- U.S. strikes have slowed Iraq militants but not weakened them - Pentagon
- Modi slams whispering campaign against Rajnath Singh
- Islamic State executes soldiers, takes hostages at Syria base - social media
- India's coal crunch - a chance to revamp, reallocate and revive
- Sensex, Nifty mark record closing high on Euro zone stimulus talk
COAL BLOCK ALLOCATIONS
A Supreme Court ruling this week that India's decades-old method of granting coal mining concessions is illegal could herald much-needed reforms in a sector long dogged by the inability of state-run Coal India to raise output fast enough. Read
Kleiner to invest in messaging startup Snapchat at near-$10 bln valuation - report. Full Article